8 months ago
IRON
AnalystsMartin AusterMartin Auster's Stock Forecasts
AnalystsMartin Auster
Sectors:
Analyst Ranking
Top 20%
#1046 out of 5290 analysts
Average Return
+7.49%
Win Rate
54%22 out of 41
Risk vs Reward
Poor
Good
Martin Auster's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Forty Seven IncFTSV | +175.60% | $34.66 | $95.51 | 2019-12-10 - 2020-04-06 | Buy |
Insmed IncINSM | +141.87% | $15.50 | $37.49 | 2020-03-17 - 2021-03-17 | Buy |
Prometheus Biosciences IncRXDX | +102.65% | $18.85 | $38.20 | 2021-04-06 - 2022-04-05 | Buy |
Dyne Therapeutics IncDYN | +95.54% | $9.20 | $17.99 | 2025-07-29 - 2026-06-03 | Buy |
Avexis IncAVXS | +64.10% | $75.31 | $123.58 | 2017-03-30 - 2018-03-29 | Strong Buy |
Martin Auster Analyst Color
Get additional color on Martin Auster's coverage of popular stocks
Martin Auster's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Equillium IncEQ | 1 | Strong Buy | $6.00 | +92.93% | Initiates Coverage On | 2 months ago |
Spyre Therapeutics IncSYRE | 1 | Strong Buy | $80.00 | +8.81% | Initiates Coverage On | 2 months ago |
Evommune IncEVMN | 1 | Strong Buy | $40.00 | +102.74% | Initiates Coverage On | 5 months ago |
Septerna IncSEPN | 1 | Strong Buy | $38.00 | +24.39% | Initiates Coverage On | 6 months ago |
Bridgebio Pharma IncBBIO | 2 | Buy | $71.00 | +8.43% | Reiterates | 7 months ago |
Disc Medicine IncIRON | 1 | Strong Buy | $108.00 | +53.52% | Maintains | 8 months ago |
Ascendis Pharma AASND | 1 | Strong Buy | $271.00 | +25.01% | Initiates Coverage On | 8 months ago |
Dyne Therapeutics IncDYN | 2 | Strong Buy | $35.00 | +94.55% | Upgrades | 9 months ago |
Alnylam Pharmaceuticals IncALNY | 2 | Buy | $424.00 | +44.92% | Reiterates | 10 months ago |
Biomarin Pharmaceutical IncBMRN | 2 | Strong Buy | $120.00 | N/A | Initiates Coverage On | 3 years ago |
Ultragenyx Pharmaceutical IncRARE | 1 | Buy | $105.00 | N/A | Upgrades | 4 years ago |
Arena Pharmaceuticals IncARNA | 2 | Hold | $100.00 | N/A | Downgrades | 4 years ago |
Flexion Therapeutics IncFLXN1 | 2 | Buy | $17.00 | N/A | Maintains | 5 years ago |
Prometheus Biosciences IncRXDX | 1 | Buy | $30.00 | N/A | Initiates Coverage On | 5 years ago |
Fulcrum Therapeutics IncFULC | 1 | Buy | $26.00 | N/A | Initiates Coverage On | 5 years ago |
Solid Biosciences IncSLDB | 4 | Hold | $120.00 | N/A | Maintains | 5 years ago |
Damora Therapeutics IncDMRA | 2 | Buy | $300.00 | N/A | Maintains | 5 years ago |
Stoke Therapeutics IncSTOK | 2 | Buy | $58.00 | N/A | Maintains | 5 years ago |
United Therapeutics CorpUTHR | 3 | Buy | $196.00 | N/A | Maintains | 5 years ago |
Alx Oncology Holdings IncALXO | 2 | Buy | $98.00 | N/A | Maintains | 5 years ago |
Insmed IncINSM | 2 | Buy | $60.00 | N/A | Maintains | 5 years ago |
Scholar Rock Holding CorpSRRK | 1 | Buy | $65.00 | N/A | Initiates Coverage On | 5 years ago |
Sarepta Therapeutics IncSRPT | 2 | Hold | $73.00 | N/A | Maintains | 5 years ago |
Uniqure NvQURE | 1 | Buy | $78.00 | N/A | Maintains | 6 years ago |
Kura Oncology IncKURA | 2 | Buy | $43.00 | N/A | Maintains | 6 years ago |
Myokardia IncMYOK | 1 | Hold | $225.00 | N/A | Downgrades | 6 years ago |
Curevac NvCVAC | 1 | Hold | $68.00 | N/A | Initiates Coverage On | 6 years ago |
Esperion Therapeutics IncESPR | 1 | Hold | $45.00 | N/A | Downgrades | 6 years ago |
Avidity Biosciences IncRNAM | 1 | Buy | $34.00 | N/A | Initiates Coverage On | 6 years ago |
Acceleron Pharma IncXLRN | 1 | Buy | $134.00 | N/A | Maintains | 6 years ago |
Intellia Therapeutics IncNTLA | 1 | Hold | $21.00 | N/A | Maintains | 6 years ago |
Anaptysbio IncANAB | 1 | Hold | $16.00 | N/A | Maintains | 6 years ago |
Forty Seven IncFTSV | 1 | Buy | $38.00 | N/A | Maintains | 6 years ago |
Spark Therapeutics IncONCE | 3 | Hold | $53.00 | N/A | Maintains | 8 years ago |
Avexis IncAVXS | 2 | Hold | N/A | N/A | Downgrades | 8 years ago |
Alexion Pharmaceuticals IncALXN | 1 | Strong Buy | N/A | N/A | Initiates Coverage On | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.